Fig. 1 · Structure

Documents & Downloads

Gadodiamide

Cat. No. A10415 CAS 131410-48-5
Gadodiamide is a gadolinium-based MRI contrast agent, used in MR imaging procedures to assist in the visualization of blood vessels.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Gadodiamide Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Gadodiamide from 2 published references. In vitro models include primary human neonatal foreskin dermal fibroblasts, passages 2–3.

Gadodiamide In Vitro Studies

In primary human dermal fibroblasts, Omniscan exposure for three days increased cell-layer type I collagen deposition without increasing secreted type I procollagen. This formulation-specific result supports altered collagen turnover as a hypothesis; it does not establish clinical fibrosis causation. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Collagen deposition and procollagen production in dermal fibroblasts

Cell-based study · Primary human neonatal foreskin dermal fibroblasts, passages 2–3 [1]

After three days, Omniscan increased cell-layer type I collagen deposition without increasing secreted type I procollagen. These findings support altered collagen turnover as a hypothesis; direct suppression of collagen degradation and causation of nephrogenic systemic fibrosis were not established.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Type I collagen in cell-layer lysatesRelative collagen deposition Increased at 50 and 250 µM; p<0.05 versus control; n=5 separate experiments; means and standard errors shown.[1]
Secreted type I procollagenProcollagen production No increase at 50 or 250 µM; n=5 separate experiments; means and standard errors shown.[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 or 250 µM Omniscan, expressed with respect to gadodiamide
Exposure duration
3 days
Method
Exposure in Ca2+-supplemented keratinocyte growth medium containing EGF and insulin.
Vehicle
Aqueous commercial formulation diluted into culture medium; control was growth medium without Omniscan.
Reported limits
No formulation-excipient-only control described for this experiment; therefore the response is attributed to Omniscan exposure, not isolated gadodiamide alone.
Methods and source locations

Compound reported in the paper: Gadodiamide; Compound label in the paper: Omniscan (GE Healthcare)

Formulation-specific cellular findings. No claim of Adooq lot validation or clinical fibrosis induction.

Materials and Methods: Omniscan and other reagents; Human dermal fibroblasts; Proliferation assay; Type I procollagen; Type I collagen. Results: Human dermal fibroblast response, Figure 1 and caption.

Type I collagen in cell-layer lysates: Western blotting, equal total-protein loading; β-tubulin control reported in the Figure 1 caption. No exact fold values inferred from bars. — Figure 1 lower panel and caption; Results: Human dermal fibroblast response.

Secreted type I procollagen: ELISA of culture fluid. Figure shows lower mean values; no claim of statistically significant suppression. — Figure 1 upper panel and caption; Results: Human dermal fibroblast response.

Gadodiamide In Vivo Studies

Following repeated intravenous gadodiamide in healthy male rats, brain gadolinium remained measurable through 50 weeks. Light microscopy and ultrastructural examination found no treatment-related brain morphology changes under the reported conditions. Functional neurological safety was not established. [2]

After a single 0.6 mmol/kg intravenous gadodiamide dose in healthy male rats, total gadolinium declined in cerebellum, kidney and femur but remained measurable at 20 weeks. These measurements do not distinguish intact gadodiamide from other gadolinium-containing species, and the kinetic study lacked untreated controls. [2]

Brain retention and morphology after repeated gadodiamide

Animal study · Healthy male Sprague Dawley rats, 6 weeks old at purchase; n=6 per group/time point for repeat-dose brain ICP-MS and histopathology; TEM n=3 per group. [2]

Measurable brain gadolinium persisted through 50 weeks after repeated dosing. No treatment-related brain morphology changes were reported by light microscopy or TEM. Morphological observations do not establish absence of functional effects.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Whole-brain gadolinium after the repeat-dose courseTotal gadolinium concentration 1 week: 2.59 ± 0.30 nmol/g; 20 weeks: 1.38 ± 0.11 nmol/g; 50 weeks: 1.56 ± 0.19 nmol/g (mean ± SD; n=6 per group).[2]
Treatment-related brain morphological findingsHistopathology and ultrastructure No treatment-related morphological effects reported; histopathology n=6 per group; TEM n=3 per group at 20 and 50 weeks.[2]

Conditions shared by the study groups

Route
Intravenous, lateral tail vein
Frequency
4 times weekly
Treatment course
5 weeks; follow-up through 50 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Repeated gadodiamide
0.6 mmol/kg per injection; cumulative 12 mmol/kg
Saline-treated ratsPersistent brain Gd with no reported treatment-related brain morphology changes.[2]
Repeated gadodiamide
Model: Healthy male Sprague Dawley rats, 6 weeks old at purchase; n=6 per group/time point for repeat-dose brain ICP-MS and histopathology; TEM n=3 per group.
Methods and source locations

Compound reported in the paper: Gadodiamide; Compound label in the paper: Gadodiamide supplied by GE Healthcare; brand and excipient composition not specified in the read methods

Healthy male rat retention and morphological observations under a high cumulative exposure; no human safety inference.

Materials and methods: Animals; Histopathology; Transmission electron microscopy ultrastructural analysis; ICP-MS. Results: Trace levels persisted; Table 1; Figure 1 and caption; Discussion limitations.

Whole-brain gadolinium after the repeat-dose course: ICP-MS on one hemisphere; total elemental Gd, without chemical speciation. — Table 1, including SD column and caption; ICP-MS methods.

Treatment-related brain morphological findings: Independent toxicologic histopathologist assessed light microscopy at three brain levels; TEM of deep cerebellar nuclei, treatment-blinded. Incidental findings occurred in controls and treated groups. — Histopathology and TEM ultrastructural methods; Results first subsection; Figure 1 and caption.

Repeated gadodiamide · Materials and methods: Animals; Histopathology; Transmission electron microscopy ultrastructural analysis; ICP-MS. Results: Trace levels persisted; Table 1; Figure 1 and caption; Discussion limitations.

Tissue gadolinium after a single gadodiamide injection

Animal study · Healthy male Sprague Dawley rats; n=3 per sampling time point; separate single-dose cohorts studied at QPS. [2]

Total gadolinium in cerebellum, kidney and femur declined between 1 hour and 20 weeks but remained measurable. Tissue kinetics measure total Gd and cannot determine how much remains as intact gadodiamide. The design had no untreated kinetic-control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Whole-cerebellum total gadoliniumConcentration 1 h: 3.86 ± 1.87 nmol/g; 20 weeks: 0.18 ± 0.02 nmol/g (mean ± SD; n=3 per time point).[2]
Left-kidney total gadoliniumConcentration 1 h: 974.55 ± 82.87 nmol/g; 20 weeks: 4.64 ± 1.21 nmol/g (mean ± SD; n=3 per time point).[2]
Femur total gadoliniumConcentration 1 h: 81.69 ± 67.46 nmol/g; 1 day: 18.46 ± 1.96 nmol/g; 20 weeks: 14.00 ± 0.06 nmol/g (mean ± SD; n=3 per time point).[2]

Conditions shared by the study groups

Route
Intravenous, lateral tail vein
Frequency
Once
Treatment course
Follow-up through 20 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Single gadodiamide dose
0.6 mmol/kg
Earlier treated time points; no untreated kinetics-control groupCerebellar, renal and femoral Gd remained measurable at 20 weeks after declining from 1-hour values.[2]
Single gadodiamide dose
Model: Healthy male Sprague Dawley rats; n=3 per sampling time point; separate single-dose cohorts studied at QPS.
Reported limits: Exact formulation not specified; no untreated kinetics controls.
Methods and source locations

Compound reported in the paper: Gadodiamide; Compound label in the paper: GE-supported single-dose gadodiamide study; exact formulation unspecified

Tissue total-Gd kinetics in healthy male rats at the stated dose; no human dose conversion or functional-safety conclusion.

Materials and methods: Animals; ICP-MS; Statistical analysis. Results: Gadolinium detected after single administration; Table 2 tissue rows and Table 3; Figures 4–5 and captions; Discussion limitations.

Whole-cerebellum total gadolinium: ICP-MS after transcardial perfusion; Figure 5a viewed; exact numbers taken from Table 2. — Table 2, Whole cerebellum row; Figure 5a and caption.

Left-kidney total gadolinium: ICP-MS; Figure 5b viewed; exact numbers taken from Table 2. — Table 2, Left kidney row; Figure 5b and caption.

Femur total gadolinium: ICP-MS; Figure 4g viewed; exact numbers taken from Table 2. — Table 2, Femur bones row; Figure 4g and caption.

Single gadodiamide dose · Materials and methods: Animals; ICP-MS; Statistical analysis. Results: Gadolinium detected after single administration; Table 2 tissue rows and Table 3; Figures 4–5 and captions; Discussion limitations.

Specifications

Manufacturer Adooq Bioscience
CAS Number 131410-48-5
Formula C16H26GdN5O8
Molecular Weight 573.7
Synonyms Omniscan
SMILES
CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water 90 mg/mL (152.11 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Gadodiamide Research References

  1. [1] Bhagavathula N, DaSilva M, Aslam MN, et al. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent Investigative radiology (2009). PMID: 19561517 DOI: 10.1097/rli.0b013e3181a4d7e9 Source material
  2. [2] Davies J, Marino M, Smith APL, et al. Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure Scientific reports (2021). PMID: 34230532 DOI: 10.1038/s41598-021-93147-2 Source material

Added to your cart

View Cart Checkout
Loading...